Holen Sie sich die Stockscreener-App
33.02
1.82%
0.59
Handel nachbörslich:
33.68
0.66
+2.00%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics holds the focus. Investors await the next evidence - AD HOC NEWS
Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales - Stock Titan
Stoke Therapeutics (STOK) Edges Lower as Stock Consolidates Near Key LevelsETF Flow - dars.gov.et
Responsive Playbooks and the STOK Inflection - Stock Traders Daily
Stoke completes phase 3 enrollment for Dravet syndrome drug - Investing.com UK
Stoke completes Phase 3 enrollment for Dravet drug study - grafa.com
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - BioSpace
Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Stud - GuruFocus
Stoke Therapeutics (STOK) Advances Phase 3 Study and NDA Plans - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial - TipRanks
Stoke completes phase 3 enrollment for Dravet syndrome drug By Investing.com - Investing.com Canada
Stoke CEO Ian Smith to speak April 14 at Needham healthcare event - Stock Titan
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027 - TradingView
Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA - Stock Titan
Dravet Syndrome Foundation (DSF) Announces 2026 Community Award Winners - EIN Presswire
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Index - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index - marketscreener.com
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)? - simplywall.st
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
STOK Forecast — Price Target — Prediction for 2027 - TradingView
Stoke Therapeutics, Inc. Actuals & Estimates (NASDAQ:STOK) - TradingView
0GT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Enterprise value to EBITDA forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Enterprise value to EBITDA forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Price to book forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics (STOK) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Stoke Therapeutics StockLong-term strategy and genetic medicine pipeline - AD HOC NEWS
Understanding the Setup: (STOK) and Scalable Risk - Stock Traders Daily
Stoke Therapeutics general counsel sells $43,637 in common stock By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel sells $43,637 in common stock - Investing.com UK
Insider Sell Alert: Jonathan Allan Sells Shares of Stoke Therape - GuruFocus
Stoke Therapeutics (STOK) legal chief sells 1,457 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 16, 2026 - BioSpace
Insider sales at STOK (NASDAQ: STOK) list 27,481 shares in March 2026 - Stock Titan
Stoke Therapeutics Stock (US86150R1023): Analyst Sentiment and Valuation Come Into Focus - AD HOC NEWS
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6%Should You Buy? - MarketBeat
STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028 - TradingView
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):